Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$10.10 USD
-0.66 (-6.13%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $10.30 +0.20 (1.98%) 5:52 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RAPT 10.10 -0.66(-6.13%)
Will RAPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RAPT
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for July 15th
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
New Strong Buy Stocks for July 15th
Other News for RAPT
RAPT Therapeutics (RAPT) Receives Neutral Rating Upgrade by JP Morgan | RAPT Stock News
JPMorgan Adjusts Rapt Therapeutics (RAPT) Rating with New Price Target
Rapt Therapeutics just upgraded at JPMorgan, here's why
RAPT Receives Outperform Rating with Promising Market Potential | RAPT Stock News
LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset